Class II recall: Regeneron Pharmaceuticals Inc: Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Inf
Regeneron Pharmaceuticals has issued a Class II recall of Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), single-dose vials for intravenous infusion after dilution, NDC 61755-008-01. The recall notice cites a lack of assurance of sterility as the reason. The FDA classification indicates this is a Class II recall.
Most relevant for: patients with cutaneous squamous cell carcinoma receiving intravenous cemiplimab treatment
Read the original at FDA Drug Enforcement ReportsSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More family medicine updates
- Long-Acting Injectable HIV Therapy Noninferior for Adherence ChallengesOct 15, 2026
- 8-week sofosbuvir-velpatasvir regimen non-inferior to 12 weeks for HCVSep 30, 2026
- Lean MASLD shows milder histology but similar mortality outcomesSep 30, 2026
- Oral GLP-1 orforglipron shows cardiovascular non-inferiority to insulin glargineSep 30, 2026
- Retatrutide produces substantial weight loss in phase 3 diabetes trialSep 29, 2026